BridgeBio Pharma (BBIO) return on equity (ROE)

Return on equity · fiscal 2020
-872.9%

BridgeBio Pharma (BBIO) earned a return on equity of -872.9% in fiscal 2020 (the year ended December 31, 2020). That is 802.3 percentage points lower than the -70.7% of fiscal 2019. Figures as of 18 Nov 2026, 02:56 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2020
-872.9%
Change on fiscal 2019
−802.3 pts
Highest on record
-51.1%fiscal 2017
Lowest on record
-872.9%fiscal 2020
Fiscal years on record
42017–2020

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

BridgeBio Pharma return on equity (ROE), in more detail

Across the 4 fiscal years on record (2017–2020), the highest was -51.1% in fiscal 2017 and the lowest -872.9% in fiscal 2020. The fiscal 2020 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -53.8%.

History · 4 fiscal years

Return on equity by fiscal year

BridgeBio Pharma return on equity (ROE), year by year

BridgeBio Pharma (BBIO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2020-872.9% 802.3 pts down
2019-70.7% 16.8 pts down
2018-53.8% 2.8 pts down
2017-51.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of BridgeBio Pharma and comparable companies
CompanyReturn on equityFiscal year
ICON ICLR2.5%2025
Jazz Pharmaceuticals JAZZ-8.2%2025
Solventum SOLV30.8%2025
BridgeBio Pharma BBIO-872.9%2020
Summit Therapeutics SMMT-163.9%2025
Glaukos GKOS-28.6%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BBIO

BridgeBio Pharma, figure by figure

BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value

BridgeBio Pharma return on equity (ROE): questions and answers

What is BridgeBio Pharma's return on equity?

BridgeBio Pharma (BBIO) earned a return on equity of -872.9% in fiscal 2020 (the year ended December 31, 2020). That is 802.3 percentage points lower than the -70.7% of fiscal 2019.

Is BridgeBio Pharma's return on equity high or low compared with its own history?

The fiscal 2020 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -53.8%.

What are the highest and lowest return on equity figures on record for BridgeBio Pharma?

Across the 4 fiscal years on record (2017–2020), the highest was -51.1% in fiscal 2017 and the lowest -872.9% in fiscal 2020.

How is BridgeBio Pharma's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BridgeBio Pharma (BBIO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/BBIO/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.